Co­herus ex­its TIG­IT deal with Jun­shi, three months af­ter Sur­face On­col­o­gy buy­out

Co­herus Bio­Sciences is walk­ing away from a three-year TIG­IT pact with Shang­hai Jun­shi Bio­sciences, sev­er­al months af­ter it ac­quired Sur­face On­col­o­gy and its TIG­IT drug.

Co­herus de­liv­ered a no­tice of ter­mi­na­tion to Jun­shi on Jan. 10, ac­cord­ing to an SEC fil­ing. The duo’s re­la­tion­ship dates back to 2021, when Co­herus paid $150 mil­lion up­front to li­cense US and Cana­di­an rights to Jun­shi’s an­ti-PD-1 drug, tori­pal­imab. As part of that deal, the biotech al­so got an op­tion for Jun­shi’s TIG­IT-tar­get­ing an­ti­body, JS006.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER